These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. Lopatin YM; Rosano GM; Fragasso G; Lopaschuk GD; Seferovic PM; Gowdak LH; Vinereanu D; Hamid MA; Jourdain P; Ponikowski P Int J Cardiol; 2016 Jan; 203():909-15. PubMed ID: 26618252 [TBL] [Abstract][Full Text] [Related]
49. Trimetazidine: the future of cardiac function? Di Napoli P; Taccardi AA Future Cardiol; 2009 Sep; 5(5):421-4. PubMed ID: 19715405 [No Abstract] [Full Text] [Related]
50. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Lee L; Horowitz J; Frenneaux M Eur Heart J; 2004 Apr; 25(8):634-41. PubMed ID: 15084367 [TBL] [Abstract][Full Text] [Related]
51. [Trimetazidine in the Treatment of Chronic HeartFailure]. Zhirov IV; Osmolovskaya YF; Tereshchenko SN Kardiologiia; 2016 Jan; 56(1):79-85. PubMed ID: 28294737 [TBL] [Abstract][Full Text] [Related]
52. Meeting the challenge of chronic ischaemic heart disease with trimetazidine. Marzilli M; Affinito S Coron Artery Dis; 2005 Nov; 16 Suppl 1():S23-7. PubMed ID: 16340400 [TBL] [Abstract][Full Text] [Related]
53. [Mechanisms of myocardial cell protection from ischemia/reperfusion injury and potential clinical implications]. Lamendola P; Di Monaco A; Barone L; Pisanello C; Lanza GA; Crea F G Ital Cardiol (Rome); 2009 Jan; 10(1):28-36. PubMed ID: 19292017 [TBL] [Abstract][Full Text] [Related]
54. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Gao D; Ning N; Niu X; Hao G; Meng Z Heart; 2011 Feb; 97(4):278-86. PubMed ID: 21134903 [TBL] [Abstract][Full Text] [Related]
55. Prognostic relevance of metabolic approach in patients with heart failure. Di Napoli P; Barsotti A Curr Pharm Des; 2009; 15(8):883-92. PubMed ID: 19275652 [TBL] [Abstract][Full Text] [Related]
56. Current Clinical Evidence of Trimetazidine in the Management of Heart Disease in Patients with Diabetes. Mahajan S; Mahajan AU J Assoc Physicians India; 2020 Nov; 68(11):46-50. PubMed ID: 33187037 [TBL] [Abstract][Full Text] [Related]
57. Energy substrate metabolism, myocardial ischemia, and targets for pharmacotherapy. Taegtmeyer H; King LM; Jones BE Am J Cardiol; 1998 Sep; 82(5A):54K-60K. PubMed ID: 9737487 [TBL] [Abstract][Full Text] [Related]
58. Trimetazidine and cardioprotection: facts and perspectives. Tsioufis K; Andrikopoulos G; Manolis A Angiology; 2015 Mar; 66(3):204-10. PubMed ID: 24719262 [TBL] [Abstract][Full Text] [Related]
59. [Ischemic heart disease and left ventricular dysfunction: the role of trimetazidine]. Belardinelli R Ital Heart J; 2004 Mar; 5 Suppl 2():23S-28S. PubMed ID: 15074774 [TBL] [Abstract][Full Text] [Related]
60. The metabolic approach in patients with heart failure: effects on left ventricle remodeling. Tang WH Curr Pharm Des; 2009; 15(8):850-6. PubMed ID: 19275649 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]